See what CeloNova is doing about COVID-19 Read More


News & Press Releases

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

San Antonio - June 1 2020

CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced that it has successfully completed enrollment of the COBRA REDUCE randomized control trial evaluating the safety and efficacy of the COBRA PzF NanoCoated Coronary Stent (NCS) with 14-day dual antiplatelet therapy (DAPT)* compared to FDA-approved drug-eluting stents (DES) with 3 or 6 months DAPT in 996 patients at high bleeding risk (HBR) across 60 global sites.

Browse Our Archives